Background: Both, clinical and biologic manifestations of septic arthritis are long been know, but few studies of its epidemiological aspects are well-documented. Literature concerning epidemiological aspects of septic arthritis remains exceptional in Galician Autonomic Community.
Objective: The aim of this investigation was to study the etiopathogenesis and epidemiological characteristic of septic arthritis in the adult population from hospital county of Servicio Galego de Saúde (SERGAS).
Material And Methods: We conducted a retrospective study of all peripheral septic arthritis registered between 1 January 1995 and 31 December 2000 on adult population of our health district of SERGAS (127.000 inhabitants). The location, etiology, pathogenesis and epidemiological characteristics were obtained from medical records.
Results: The case records of 45 patients with 46 septic arthritis (37 native joints and 9 prosthetic joints) were registered. The mean age was 57 years and 24 patients were male. During the study period, the incidence of bacterial arthritis suffered a progressive reduction to 10.2/105 inhabitants (1995) up to 3.1/10(5) (2000) with a median of 7.2/10(5). Ten patients (22%), eight male and two women, had a post-traumatic septic arthritis. Major risk factors were diabetes mellitus (5 patients), rheumatoid arthritis (5 patients) and intravenous drug abuse (3 patients). Staphylococcus aureus was the principal causative agent (28 patients, 62%) and the knee was the most commonly affected joint (41%), followed by the hip (15%) and ankle (15%).
Conclusions: During the past six years, the incidence of adult peripheral septic arthritis in our SERGAS health district has been gradually reduced. Trauma was a important factor in the development of septic arthritis through direct inoculation or through spread from adjacent infectious focus. The major systemic factors predisposing to joint infection were rheumatoid arthritis and diabetes mellitus. In both, native and prosthetic joints, Staphylococcus aureus was the most common isolated pathogen.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders.
Cytokine Growth Factor Rev
January 2025
MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Lincoln, NE, USA. Electronic address:
IL-17A, referred to as IL-17, is the founding member of a family of pro-inflammatory cytokines, including IL-17B, IL-17C, IL-17D, IL-17E (or IL-25), and IL-17F, which act via receptors IL-17RA to IL-17RE, and elicit potent cellular responses that impact diverse diseases. IL-17's interactions with various cytokines include forming a heterodimer with IL-17F and being stimulated by IL-23's activation of Th17 cells, which can lead to inflammation and autoimmunity. IL-17 is implicated in infectious diseases and inflammatory disorders such as rheumatoid arthritis and psoriasis, promoting neutrophil recruitment and anti-bacterial immunity, but potentially exacerbating fungal and viral infections, revealing its dual role as protective and pathologic.
View Article and Find Full Text PDFIndoxyl sulfate (IS) mediates pro-inflammatory responses in severe pneumonia in patients with rheumatoid arthritis associated interstitial lung disease.
Clin Immunol
January 2025
National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology, China; Department of Rheumatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:
Object: Patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) have a high risk of serious infection, in particular severe pneumonia. This study aimed to investigate the transcriptional landscape, lower respiratory tract (LRT) microbiome and metabolomic profiles in the lung of RA-ILD patients with pneumonia.
Method: A total of 10 RA-ILD with pneumonia were enrolled in this study.
Ureaplasma urealyticum septic hip arthritis associated with ocrelizumab therapy in a young patient with multiple sclerosis.
Rev Neurol (Paris)
January 2025
Clinical Neuroscience Centre, CIC_P1414 Inserm, University Hospital, Rennes, France. Electronic address:
Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial.
Ann Rheum Dis
January 2025
Rheumatology Center, Toulouse University Hospital, Toulouse, France.
Objectives: To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA).
Methods: The Strategies for glucocorticoid TApering in Rheumatoid arthritis (STAR) study was a double- blind, double-placebo randomised controlled trial including patients with RA receiving a stable dose of glucocorticoid 5 mg/day for ≥3 months and were in LDA for ≥3 months. Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before discontinuation or to taper prednisone by 1 mg/day every month until complete discontinuation, contingent on maintaining LDA.
Specific immune response to and ability to control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection.
Front Immunol
January 2025
Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
Background: Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, with tuberculosis infection (TBI), have a high probability of progressing to tuberculosis disease (TB). We aim to characterize the impact of IMID on the immune response to (Mtb) in patients with TBI and TB disease.
Methods: We enrolled TBI and TB patients with and without IMID.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!